This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

GLP-1 receptor agonists and chronic obstructive pulmonary disease (COPD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A longitudinal cohort study was undertaken to compare the risk of cardiopulmonary outcomes in patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disease (COPD) using glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) (1):

  • registry study in Taiwan (8,060 matched GLP-1 receptor agonists (RA) users and non-users with COPD and type 2 diabetes) found those on GLP-1 RA had a lower risk of mortality (adjusted hazard ratio 0.46, 95%CI 0.38-0.56), cardiovascular events (0.73, 0.65-0.82), and bacterial pneumonia (0.76, 0.65-0.80

Study authors concluded:

  • study showed that GLP-1 RAs had a lower risk of cardiopulmonary outcomes and all-cause mortality than non-GLP1 RAs in patients with T2D and COPD
    • GLP-1 RAs may help manage diabetes in people with COPD

Reference:

  1. Yen FS, Hsu CC, Wei JC, Tsai FJ, Huang Y, Yu TS, Hwu CM. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024 Oct 1:thorax-2023-221040. doi: 10.1136/thorax-2023-221040.

 

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.